{"contentid": 488051, "importid": NaN, "name": "Orphan drug candidate blossoms in Japan", "introduction": "A novel treatment for the viral disease CMV viremia, TAK-620 (maribavir), has generated positive results in the Phase III SOLSTICE trial.", "content": "<p>A novel treatment for the viral disease CMV viremia, TAK-620 (maribavir), has generated positive results in the Phase III SOLSTICE trial.</p>\n<p>Japanese pharma major Takeda Pharmaceutical (TYO: 4502) presented the data during a Presidential Symposium at the annual meeting of the European Society for Blood and Marrow Transplantation (EBMT).</p>\n<p>Results from a subgroup analysis show greater than three times as many (62.8%) transplant recipients in the test group achieved clearance after eight weeks, compared with those who received investigator assigned treatment.</p>\n<p>Transplant recipients in the subgroup receiving maribavir exhibited lower incidence of treatment-related toxicities common with conventional antiviral therapies, Takeda said.</p>\n<p>Overall, 67% of those treated with maribavir experienced side effects, and serious adverse events including diarrhea and renal failure were much more common in this group, compared with those given Valcyte (valganciclovir).</p>\n<p>However, given the severity of the condition and the lack of alternatives, regulators will likely not consider that an impediment to approval.</p>\n<h2>Maribavir development</h2>\n<p>The CMV virus is very widespread, and is normally safely controlled by a healthy immune system. For those who receive a transplant, immunosuppressants can result in a flare up of the virus, leading to serious disease.</p>\n<p>Maribavir, an orphan drug-designated antiviral agent, is currently the only investigational therapy in development for this patient population.</p>\n<p>Originally part of ViroPharma&rsquo;s pipeline, the therapy was picked up by Shire, and subsequently by Takeda via its $64 billion acquisition of the rare disease specialist.</p>\n<p>The detailed results build on previously released top-line data showing the SOLSTICE trial met its primary efficacy endpoint.</p>\n<p>Rafael Duarte, of Madrid-based Hospital Universitario Puerta de Hierro, said: &ldquo;Transplant recipients with CMV infections resistant to conventional antiviral therapies are some of the hardest to treat.&rdquo;</p>\n<p>He added: &ldquo;We believe these data are important as they build on previously presented results supporting the potential of maribavir, which, if approved, could transform the management of CMV in these patients.\"</p>", "date": "2021-03-16 12:38:00", "meta_title": NaN, "meta_keywords": "maribavir, results, disease, treatment, trial, SOLSTICE, transplant, candidate, orphan, drug, Japan, blossoms, generated, positive, TAK-, Phase, viremia", "meta_description": "A novel treatment for the viral disease CMV viremia, TAK-620 (maribavir), has generated positive results in the Phase III SOLSTICE trial.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-16 11:57:16", "updated": "2021-03-16 17:31:12", "access": NaN, "url": "https://www.thepharmaletter.com/article/orphan-drug-candidate-blossoms-in-japan", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "2020_biotech_lab_vials_big.jpg", "image2id": "2020_biotech_lab_vials_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Anti-virals, Infectious diseases", "topic_tag": "Conferences, Drug Trial, Research", "geography_tag": "Japan", "company_tag": "Takeda", "drug_tag": "maribavir", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-16 12:38:00"}